HC Wainwright & Co. Maintains Buy on Pyxis Oncology, Raises Price Target to $8

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Pyxis Oncology (NASDAQ:PYXS) with a Buy and raises the price target from $7 to $8.